Compass Pathways has been granted a patent for a method of treating anxiety disorders using psilocybin. The method involves administering a therapeutically effective dose of crystalline psilocybin with high chemical purity orally to patients. GlobalData’s report on Compass Pathways gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Compass Pathways Plc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Compass Pathways, was a key innovation area identified from patents. Compass Pathways's grant share as of February 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for treating anxiety disorder with crystalline psilocybin

Source: United States Patent and Trademark Office (USPTO). Credit: Compass Pathways Plc

A recently granted patent (Publication Number: US11865126B2) outlines a method for treating anxiety disorders in patients using crystalline psilocybin. The method involves orally administering a therapeutically effective amount of an oral dosage form containing crystalline psilocybin with specific X-ray powder diffraction (XRPD) peaks and a chemical purity exceeding 97%, along with a pharmaceutically acceptable excipient. The dosage ranges from 1 mg to 40 mg of crystalline psilocybin, with variations in dosages specified for different levels of treatment intensity.

Furthermore, the patent details the administration of psilocybin for anxiety disorder treatment, emphasizing the importance of the crystalline form's characteristics and purity. Dosage amounts, ranging from 1 mg to 40 mg, are tailored to suit the severity of the patient's condition, with specific XRPD peaks and purity levels ensuring the effectiveness of the treatment. The method is applicable to various anxiety disorders, including acute stress disorder, panic disorders, phobias, and social anxiety disorders, among others, catering to patients of different age groups, from under 18 to over 40 years old.

To know more about GlobalData’s detailed insights on Compass Pathways, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies